Micafungin Pharmazac (Micafungin)

Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is essential for producing β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. This inhibition weakens the wall, leading to osmotic instability and cell death, particularly against Candida organisms.

The dosing regimen for Micafungin Pharmazac is determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals follow approved guidelines and adjust the dose as needed for each individual case.

Safety data for micafungin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made by the treating physician.

To order Micafungin Pharmazac, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Micafungin belongs to the echinocandin class, which differs from azoles and polyenes. Echinocandins target the fungal cell wall, offering rapid fungicidal activity against most Candida species, including some azole‑resistant strains. Unlike polyenes such as amphotericin B, micafungin has a lower risk of nephrotoxicity, but it is administered intravenously rather than orally.

Micafungin Pharmazac must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and do not freeze or shake the solution. Before administration, allow the product to reach room temperature if required by the preparation instructions.

Micafungin Pharmazac is administered by intravenous infusion, typically over a period of 1 hour. The infusion rate and total daily dose are set by the prescriber according to the indication and patient characteristics. Infusion should be performed using aseptic technique and appropriate IV equipment.

Serious adverse events include severe hepatic dysfunction, anaphylactic reactions, Stevens‑Johnson syndrome or toxic epidermal necrolysis, acute renal impairment, and profound neutropenia. Patients should be monitored closely for signs of liver injury, hypersensitivity, skin rash, and changes in renal function or blood counts during therapy.

Micafungin Pharmazac is contraindicated in individuals with a known hypersensitivity to micafungin or any other echinocandin. Caution is advised for patients with severe hepatic impairment, and it should be avoided in those with a history of severe allergic reactions to related compounds. The prescriber should evaluate each patient’s medical history before initiating therapy.